Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)

医学 特应性皮炎 随机对照试验 内科学 免疫学
作者
Jonathan I. Silverberg,Bruce E Strober,Brian Feinstein,Jinhua Xu,Emma Guttman‐Yassky,Eric Lawrence Simpson,Pauline Li,Malinda V. Longphre,Jing Song,Jiawang Guo,Jang Yun,Belinda Williams,Wubin Pan,Selwyn Ho,Raúl Collazo,Zheng Wei
出处
期刊:The Journal of Allergy and Clinical Immunology [Elsevier BV]
卷期号:153 (4): 1040-1049.e12 被引量:34
标识
DOI:10.1016/j.jaci.2023.11.924
摘要

Background Rademikibart (CBP-201) is a next-generation IL-4 receptor alpha–targeting antibody. Objective We sought to evaluate rademikibart in adults with moderate to severe atopic dermatitis. Methods A total of 226 patients were randomized, double-blind, to subcutaneous rademikibart (300 mg every 2 weeks [Q2W], 150 mg Q2W, 300 mg every 4 weeks [Q4W]; plus 600-mg loading dose) or placebo. Randomization began in July 2020. The trial was completed in October 2021. Results The WW001 phase 2 trial achieved its primary end point: significant percent reduction from baseline in least-squares mean Eczema Area Severity Index (EASI) to week 16 with rademikibart 300 mg Q2W (−63.0%; P = .0007), 150 mg Q2W (−57.6%; P = .0067), 300 mg Q4W (−63.5%; P = .0004) versus placebo (−39.7%). EASI scores decreased significantly with 300 mg Q2W and Q4W at the earliest assessment (week 2), with no evidence of plateauing by week 16. Significant improvements were also observed in secondary end points, including pruritus. Across the primary and secondary end points, efficacy tended to be comparable with 300 mg Q2W and Q4W dosing. Rademikibart and placebo had similar, low incidence of treatment-emergent adverse events (TEAEs) (48% vs 54%), serious TEAEs (1.8% vs 3.6%), TEAEs leading to treatment discontinuation (1.2% vs 1.8%), conjunctivitis of unspecified cause (2.9% vs 0%), herpes (0.6% vs 1.8%), and injection-site reactions (1.8% vs 1.8%). Although no discontinuations were attributed to coronavirus disease 2019, pandemic-related restrictions likely had an impact on trial conduct. Conclusions Rademikibart was efficacious and well tolerated at Q2W and Q4W intervals. Q4W dosing is a more convenient frequency than approved for current therapies. Rademikibart (CBP-201) is a next-generation IL-4 receptor alpha–targeting antibody. We sought to evaluate rademikibart in adults with moderate to severe atopic dermatitis. A total of 226 patients were randomized, double-blind, to subcutaneous rademikibart (300 mg every 2 weeks [Q2W], 150 mg Q2W, 300 mg every 4 weeks [Q4W]; plus 600-mg loading dose) or placebo. Randomization began in July 2020. The trial was completed in October 2021. The WW001 phase 2 trial achieved its primary end point: significant percent reduction from baseline in least-squares mean Eczema Area Severity Index (EASI) to week 16 with rademikibart 300 mg Q2W (−63.0%; P = .0007), 150 mg Q2W (−57.6%; P = .0067), 300 mg Q4W (−63.5%; P = .0004) versus placebo (−39.7%). EASI scores decreased significantly with 300 mg Q2W and Q4W at the earliest assessment (week 2), with no evidence of plateauing by week 16. Significant improvements were also observed in secondary end points, including pruritus. Across the primary and secondary end points, efficacy tended to be comparable with 300 mg Q2W and Q4W dosing. Rademikibart and placebo had similar, low incidence of treatment-emergent adverse events (TEAEs) (48% vs 54%), serious TEAEs (1.8% vs 3.6%), TEAEs leading to treatment discontinuation (1.2% vs 1.8%), conjunctivitis of unspecified cause (2.9% vs 0%), herpes (0.6% vs 1.8%), and injection-site reactions (1.8% vs 1.8%). Although no discontinuations were attributed to coronavirus disease 2019, pandemic-related restrictions likely had an impact on trial conduct. Rademikibart was efficacious and well tolerated at Q2W and Q4W intervals. Q4W dosing is a more convenient frequency than approved for current therapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
Gaoyuanhong666完成签到 ,获得积分10
1秒前
古雨林发布了新的文献求助50
1秒前
Zoe柑完成签到,获得积分10
3秒前
3秒前
锂离子发布了新的文献求助10
3秒前
3秒前
3秒前
将将好发布了新的文献求助10
4秒前
4秒前
陈谨诺完成签到,获得积分10
4秒前
4秒前
4秒前
张一行完成签到,获得积分20
4秒前
4秒前
Tina完成签到 ,获得积分10
5秒前
罗大侠发布了新的文献求助10
6秒前
6秒前
molihuakai的应助被这次会赢吗采纳,获得10
6秒前
Orange的应助被祁忆采纳,获得10
6秒前
Wenroy完成签到,获得积分10
7秒前
7秒前
王晨发布了新的文献求助30
7秒前
sli完成签到,获得积分10
7秒前
张一行发布了新的文献求助10
7秒前
brynn完成签到 ,获得积分10
7秒前
ft4完成签到,获得积分10
8秒前
细腻黄豆发布了新的文献求助10
8秒前
现代海蓝完成签到,获得积分10
8秒前
8秒前
hammer发布了新的文献求助10
8秒前
Orange的应助被宋清华采纳,获得10
10秒前
嘻嘻哈哈的应助被zhangzhuopu采纳,获得10
10秒前
10秒前
2368372311发布了新的文献求助10
11秒前
11秒前
wangfei发布了新的文献求助10
12秒前
zaaa发布了新的文献求助10
13秒前
上官若男的应助被xiaomili采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188013
求助须知:如何正确求助?哪些是违规求助? 9575913
关于积分的说明 21844012
捐赠科研通 7785789
什么是DOI,文献DOI怎么找? 3435148
关于科研通互助平台的介绍 2559521
邀请新用户注册赠送积分活动 2482051